21:37 , Feb 14, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

New Therapeutic Targets and Biomarkers: January 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January. Therapeutic targets are defined as any protein, gene or other molecule...
00:07 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest promoting WWOX expression could help treat metastatic triple-negative breast cancer (TNBC). In patients, high expression of WWOX in primary tumor samples was associated with...
19:33 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies suggest promoting CTNNB1 citrullination or PAD2 expression could help treat colorectal cancer. Screening of approved drugs in HEK cell-based assays of CTNNB1 signaling and cell line-based citrullination...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Pilot trial data

An open-label pilot trial in 5 liver transplant patients showed that oral Alinia reduced HCV viral load in all patients during the first 72 hours post-transplant. However, HCV RNA levels were similar to pre-transplant levels...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II start

Next half, Intercell AG (VSE:ICLL; OTCQX:INRLY, Vienna, Austria) and Romark will begin a European Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's nitazoxanide with or without Pegasys...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II data

Chugai, a subsidiary of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), has exclusive rights to develop and commercialize Alinia in Japan under a 2009 deal (see BioCentury, Feb. 23, 2009). Alinia for oral suspension and Alinia tablets...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Clinical News

Alinia nitazoxanide: Phase II started

Romark began a double-blind, placebo-controlled, U.S. Phase II trial (RM01-2027) in 440 patients to evaluate 500 mg oral Alinia twice daily for 5 days. Chugai, a subsidiary of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), has exclusive...
08:00 , Jan 7, 2010 |  BC Innovations  |  Targets & Mechanisms

HCV cache: the list

Researchers at The Scripps Research Institute have used a cell-based model of HCV infection to identify compounds on the market or in development for other indications that could be repurposed to treat HCV. 1 But...
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

Extraneal regulatory update

FDA approved a boxed warning to the label of Extraneal peritoneal dialysis solution to warn of dangerous drug-device interaction. The boxed warning states that blood glucose measurement in patients receiving Extraneal must be done with...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Clinical News

Controlled release nitazoxanide: Phase II data

Data from the double-blind, placebo-controlled Phase III OPTIMA HCN-2 trial in 41 treatment-naïve patients with chronic HCV genotype 4 showed that twice-daily 675 and 1,350 mg controlled release nitazoxanide produced RVR rates of 59% and...